1. Guan, J, Wang, W, Jin, D, et al. A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients. Ther Adv Chronic Dis 2021; 12: 20406223211039699.
Google Scholar | SAGE Journals2. De Luca, G, Cavalli, G, Campochiaro, C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol 2020; 2: e465–e473 (ClinicalTrials.gov, NCT04318366).
Google Scholar | Crossref | Medline3. Temesgen, Z, Assi, M, Shweta, FNU, et al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study. Mayo Clin Proc 2020; 95: 2382–2394 (ClinicalTrials.gov, NCT04351152).
Google Scholar | Crossref | Medline4. Patel, J, Beishuizen, A, Ruiz, XB, et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). medRxiv 2021 (ClinicalTrials.gov number: NCT04376684).
Google Scholar5. Fisher, A, Veenith, T, Slade, D, et al. Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial. medRxiv 2021 (Isrctn.com, ISRCTN 40580903).
Google Scholar | Medline6. Cremer, P, Abbate, A, Hudock, K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol 2021; 3: e410–e418 (ClinicalTrials.gov, NCT04399980, NCT04463004, and NCT04492514).
Google Scholar | Crossref | Medline7. Temesgen, Z, Burger, C, Baker, J, et al. Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial. medRxiv 2021 (ClinicalTrials.gov, NCT04351152).
Google Scholar | Medline